This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Bacillus calmette-guerin substrain tice live antigen is a live attenuated vaccine against Mycobacterium bovis.
- Brand Names
- BCG Vaccine, Tice Bcg
- Generic Name
- Bacillus calmette-guerin substrain tice live antigen
- DrugBank Accession Number
- DB10343
- Background
Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- BCG, Live, Tice Strain
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept. Acyclovir The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Altretamine. Amantadine The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Amantadine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bcg Vaccine Injection, powder, lyophilized, for solution 50 mg/1 Percutaneous Merck Sharp & Dohme Corp. 1989-06-21 Not applicable US 
Oncotice Powder, for solution 50 mg/1 Intravesical Merck Ltd. 1995-12-31 Not applicable Canada 
Tice Bcg Powder, for suspension 50 mg/50mL Intravesical Merck Sharp & Dohme Corp. 1990-08-24 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2XQ558L16Z
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Percutaneous 50 mg/1 Injection, powder, for suspension Intravesical 50 mg Powder, for solution Intravesical 50 mg/1 Powder, for suspension Intravesical 50 mg/50mL Injection, powder, lyophilized, for suspension 50 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at May 28, 2022 06:24